Keytruda vs Ocrevus
Side-by-side drug price comparison from Medicare Part D data
Verdict
Keytruda costs 23% less per claim than Ocrevus ($18176.00 vs $23635.00). Ocrevus has a generic alternative available. Total Medicare spending: Keytruda at $7.2B vs Ocrevus at $3.5B.
| Metric | Keytruda | Ocrevus |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $18,176* | $23,635 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $7.2B | $3.5B |
| Total Claims | 398,000 | 148,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 28.6% | 16.5%* |
| Generic Available | No | Yes |
| Condition | Cancer | Multiple Sclerosis |
| Total Beneficiaries | 82,000 | 62,000 |
Keytruda costs 23% less per claim than Ocrevus ($18176.00 vs $23635.00). Ocrevus has a generic alternative available. Total Medicare spending: Keytruda at $7.2B vs Ocrevus at $3.5B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both entity A and entity B. What follows is the interpretation — which specific axes carry the most weight for entity A versus entity B, and which differences are large enough to influence a real decision.
Practical use of the comparison: read the data above, then drill into the individual entity A and entity B detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: CMS Medicare Part D Spending, 2026.